Scholar Rock (NASDAQ:SRRK) Insider Caryn Parlavecchio Sells 6,600 Shares

by · The Markets Daily

Scholar Rock Holding Corporation (NASDAQ:SRRK – Get Free Report) insider Caryn Parlavecchio sold 6,600 shares of the firm’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $44.48, for a total transaction of $293,568.00. Following the completion of the transaction, the insider directly owned 148,864 shares in the company, valued at approximately $6,621,470.72. This represents a 4.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Scholar Rock Stock Up 2.9%

Shares of NASDAQ SRRK opened at $46.05 on Thursday. The stock has a market cap of $4.70 billion, a PE ratio of -14.62 and a beta of 0.63. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. Scholar Rock Holding Corporation has a 12-month low of $22.71 and a 12-month high of $48.28. The company has a 50-day moving average of $43.23 and a 200 day moving average of $37.16.

Scholar Rock (NASDAQ:SRRK – Get Free Report) last released its earnings results on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same period last year, the firm earned ($0.66) EPS. As a group, sell-side analysts predict that Scholar Rock Holding Corporation will post -2.42 EPS for the current fiscal year.

Institutional Investors Weigh In On Scholar Rock

A number of institutional investors have recently made changes to their positions in the stock. Ramirez Asset Management Inc. purchased a new stake in shares of Scholar Rock in the 3rd quarter valued at approximately $37,000. Penserra Capital Management LLC acquired a new stake in Scholar Rock in the 3rd quarter valued at approximately $56,000. Strs Ohio purchased a new stake in Scholar Rock in the first quarter valued at approximately $77,000. Bessemer Group Inc. lifted its stake in Scholar Rock by 970.0% during the third quarter. Bessemer Group Inc. now owns 2,322 shares of the company’s stock worth $86,000 after purchasing an additional 2,105 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of Scholar Rock during the second quarter worth $94,000. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SRRK has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research note on Wednesday, October 8th. BMO Capital Markets restated an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a research report on Friday, November 14th. UBS Group began coverage on shares of Scholar Rock in a report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th. Finally, Wolfe Research started coverage on shares of Scholar Rock in a research report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price target on the stock. Four analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $50.14.

Get Our Latest Stock Analysis on Scholar Rock

About Scholar Rock

(Get Free Report)

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).

Recommended Stories